Leukemia & lymphoma · 2020
Primary refractory multiple myeloma: a real-world experience with 85 cases.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jurczyszyn Artur, Waszczuk-Gajda Anna, Castillo Jorge J, Krawczyk Katarzyna, Stork Martin, Pour Ludek, Usnarska-Zubkiewicz Lidia, Potoczek Stanisław, Hus Iwona, Davila Valls Julio, Hari Parameswaran, Chhabra Saurabh, Gentile Massimo, Mikala Gabor, Varga Gergely, Chim Chor Sang, Fiala Mark, Vij Ravi, Schutz Natalia, Rodzaj Marek, Porowska Agnieszka, Vesole David H, Druzd-Sitek Agnieszka, Walewski Jan, Nooka Ajay K
Аннотация
This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.